Adlai Nortye Ltd. (NASDAQ:ANL) Short Interest Update

Adlai Nortye Ltd. (NASDAQ:ANL) was the recipient of a significant increase in short interest in the month of November. As of November 15th, there was short interest totalling 4,300 shares, an increase of 38.7% from the October 31st total of 3,100 shares. Based on an average daily volume of 16,100 shares, the days-to-cover ratio is currently 0.3 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $9.00 target price on shares of Adlai Nortye in a research note on Monday, November 11th.

Adlai Nortye Trading Up 0.9 %

Shares of ANL stock traded up $0.02 during trading on Friday, hitting $2.23. The company had a trading volume of 1,954 shares, compared to its average volume of 11,709. The stock’s 50-day moving average price is $2.27 and its 200 day moving average price is $3.69. Adlai Nortye has a one year low of $1.85 and a one year high of $17.48.

Adlai Nortye Company Profile

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.